QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
← catalyst calendarSponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
190actual
Sites
28
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-06-02 | actual | When the study began enrolling |
| Primary completion | 2024-10-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2017-01-18 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bladder Cancer
Interventions
- Drug: N-803 and BCG
- Drug: N-803
Primary outcomes
what the primary-completion date above is the date OFComplete Response
measured 60 Months
Disease-Free Rate
measured 12 Months
Publications
- PMID 40956664 — linked by the registry
- PMID 38953850 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed